Anbio Biotechnology cash flow statement

In fiscal 2025, Anbio Biotechnology's operations generated −$6.7m of cash.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Anbio Biotechnology: cash flow statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	4,449	898	2,080	−6,739
Shares issued	—	0	0	7,230

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Nuwellis, Inc. cash flow
Milestone Scientific Inc. cash flow
Neuroone Medical Technologies Corp cash flow
Beyond Air, Inc. cash flow
Work Medical Technology Group LTD cash flow

Head to head: NNNN vs NUWE MLSS vs NNNN NMTC vs NNNN NNNN vs XAIR

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Anbio Biotechnology's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Anbio Biotechnology.